IMPORTANCE Iron-deficiency anemia (IDA) affects millions of persons worldwide, and is associated with impaired neurodevelopment in infants and children. Ferrous sulfate is the most commonly prescribed oral iron despite iron polysaccharide complex possibly being better tolerated.
I ron-deficiency anemia (IDA) affected more than 1 billion persons worldwide in 2010, 1,2 including up to 3% of children aged 1 to 2 years in the United States. [3] [4] [5] The most common cause of IDA in infants and young children is inadequate dietary iron intake resulting from excessive cow milk consumption, prolonged breastfeeding without appropriate iron supplementation, or both. It typically occurs in infants and young children when rapid growth outstrips availability of dietary iron. Consequences include irritability, malaise, pica, and both short-and long-term neurodevelopmental impairment. [6] [7] [8] Successful treatment of IDA requires recognition and correction of the underlying etiology accompanied by iron replacement therapy to normalize the hemoglobin concentration and replenish iron stores. Treatment failure is common due to medication nonadherence, adverse effects related to excessive dosing, and lack of evidence-based management guidelines. 9 Few randomized clinical trials inform the selection of iron preparation, dosage schedule, and duration of therapy, irrespective of the underlying etiology, age, or sex of affected individuals.
10,11
In infants and young children, standard dosing recommendations are 2 to 6 mg/kg/d of elemental iron given from 1 to 3 times daily for a duration of 3 to 6 months. 12 The literature on adults suggests that lower therapeutic dosing strategies may be sufficient for successful treatment.
13,14
Dozens of oral iron preparations (most of them overthe-counter supplements) are available for IDA treatment. Ferrous sulfate, an iron salt, is the standard and most commonly used agent to treat nutritional IDA. 15, 16 Alternatively, iron polysaccharide complex preparations containing ferric iron may be prescribed due to their potentially improved tolerability and better taste. Given the high prevalence of IDA in infants and young children, this double-blind, randomized clinical trial was designed to investigate whether an iron polysaccharide complex agent was more efficacious than ferrous sulfate in increasing hemoglobin concentration in infants and children aged 9 to 48 months with nutritional IDA.
Methods
The BESTIRON study was a randomized, double-blind singlecenter superiority trial designed to compare the efficacy of an iron polysaccharide complex (NovaFerrum, Gensavis Pharmaceuticals LLC) vs ferrous sulfate for the treatment of nutritional IDA in infants and young children who were referred for care at the Children's Medical Center in Dallas, Texas. The institutional review board at the University of Texas Southwestern Medical Center approved the study. Written informed consent was obtained from the parents of each participant prior to enrollment. The study was performed and analyzed in accordance with the Consolidated Standards of Reporting Trials. The trial start date was September 3, 2013, and it continued through November 5, 2015. The final follow-up date was January 28, 2016. A single protocol modification regarding inclusion of laboratory criteria was made prior to the enrollment of any patients and formal institutional review board approval was received the day after the first patient was enrolled. The study protocol appears in Supplement 1.
Eligible patients were infants and children aged 9 to 48 months with a diagnosis of nutritional IDA resulting from excessive cow milk intake of greater than 720 mL per day, breastfeeding without iron supplementation, or both. Given that racial and ethnic minority groups are disproportionately affected by IDA, this information was collected and reported for all patients. Data were obtained from the electronic medical record, which contains self-reported racial and ethnic identification based on fixed categories. Iron-deficiency anemia was confirmed by the following hematologic indices: hemoglobin concentration of 10 g/dL or less, mean corpuscular volume of 70 fL or less, reticulocyte hemoglobin equivalent of 25 pg or less, and either serum ferritin level of 15 ng/mL or less or total iron-binding capacity of 425 μg/dL or greater.
Patients were excluded from enrollment if they had clinical or laboratory evidence of other causes of anemia (entire list of eligibility criteria appears in eTable 1 in Supplement 2). Receipt of a packed red blood cell transfusion for severe symptomatic anemia at presentation did not exclude enrollment. All patients who received a transfusion had repeat hematologic indices assessed after the transfusion to ensure eligibility.
Enrolled patients were randomized with a 1:1 allocation to receive either oral ferrous sulfate drops (15 mg/mL) or oral iron polysaccharide complex drops (15 mg/mL). Randomization was stratified by degree of anemia (hemoglobin concentration ≥8.0 g/dL vs <8.0 g/dL). Within each stratum, patients were randomly assigned to either experimental group with a 1:1 allocation by a computer-generated randomization schedule using permuted blocks of 4.
Allocation concealment occurred after each participant was formally enrolled in the trial, and all baseline measurements (history, physical examination, laboratory assessment) were completed. Implementation of the sequence generation and allocation concealment mechanism was performed by an investigational pharmacist who had no direct contact with study patients. Trial investigators performed enrollment and all study procedures after randomization. Except for the investigational pharmacist, the members of the study team were blinded to treatment allocation.
Patients were prescribed a single daily dose of 3 mg/kg of elemental iron administered via oral syringe by the parents or caregiver at bedtime. Daily doses were rounded up to the nearest 0.5 mL. Parents or caregivers were asked not to administer other iron-containing preparations and instructed not to mix the study medication with any food or drink and specifically to avoid milk intake within 1 hour of administering the study medication. Nutritional counseling about the need to reduce cow milk intake to a maximum of 600 mL per day was provided. A daily diary with the dosing instructions was given to parents or caregivers at each visit to record medication administration and adverse effects.
Subsequent outpatient study visits were scheduled at weeks 4, 8, and 12 after enrollment to review between-interval history and perform laboratory testing (complete blood count, reticulocyte count, reticulocyte hemoglobin equivalent, serum ferritin level, serum iron level, total iron-binding capacity, and blood lead level [the latter performed during week 4 only]). Treatment failure was defined as a hemoglobin increment of less than 0.5 g/dL above the baseline concentration at week 8. The final visit at week 12 involved a comprehensive history, including whether the study drug had been mixed with other liquids or foods. Adverse effects were assessed every 2 weeks via telephone contact and at clinic visits. At each follow-up visit, returned medication bottles were submitted to the investigational pharmacy and the volume of unused study medication was measured. Further details regarding adverse effect assessment appear in the eMethods in Supplement 2.
The primary outcome was the change in hemoglobin concentration during the 12 weeks after initiation of oral iron therapy. Secondary outcomes included the proportion of patients with complete resolution of IDA (defined as hemoglobin concentration >11 g/dL, mean corpuscular volume >70 fL, reticulocyte hemoglobin equivalent >25 pg, serum ferritin level >15 ng/mL, and total iron-binding capacity <425 μg/dL at the 12-week visit), changes in other iron laboratory measures, adverse effects, lost to follow-up rates, resolution of IDA signs and symptoms, and medication adherence as measured by patient diary entries and returned medication volume.
Estimates for baseline mean hemoglobin concentration of 7.8 g/dL (SD, 1.5 g/dL) were derived from data on new patients with IDA seen at the Children's Medical Center outpatient hematology clinic during the preceding 4½-year period. 9 We hypothesized that at the time of study completion there would be a 1-g/dL between-group difference in the mean hemoglobin concentration values (ferrous sulfate: 11 g/dL; iron polysaccharide complex: 12 g/dL). The effect size of 1 g/dL was chosen as a clinically significant difference based on an analysis of studies evaluating IDA and neurocognitive outcomes by the World Health Organization and work examining the relationship between serum ferritin level and hemoglobin concentration in young children. 17, 18 We assumed a withinpatient correlation of 0.25. Using a linear mixed model and assuming a lost to follow-up rate of 25%, 9 the accrual goal was 40 patients per group (80 total) to allow for a 2-sided type I error of .05 at 80% power. We hypothesized that iron polysaccharide complex would result in a greater hematologic response compared with ferrous sulfate as measured by change in hemoglobin concentration over 12 weeks. The primary analysis consisted of a linear mixed regression model in an intention-to-treat population. It included treatment and time as covariates and patient random effects to account for correlation among longitudinal measurements from the same patients. The linear mixed model readily accommodates missing data so imputation for missing data was not performed. 19 Changes in other continuous measures were modeled with a similar linear mixed regression method. The generalized estimation equation approach was used to estimate model parameters, which accommodates incomplete data and is robust against deviation from the normality assumption. The χ 2 test was used to compare categorical outcomes, including the proportion of patients with a complete response, dropouts, adverse effects, and adherence measures. The percentage volume of unused study medication returned at each visit was compared using the Wilcoxon rank sum test. All tests were 2-sided with a significance level of .05. Adjustment for multiple comparisons of secondary end points was not performed. Inference about secondary outcomes should be interpreted as exploratory. A post hoc between-group comparison of the proportion of patients who complained of abdominal pain, constipation, vomiting, and diarrhea (combined gastrointestinal adverse effect profile) also was conducted using the χ 2 test. All analyses were performed using SAS version 9.4
(SAS Institute Inc).
Results
The trial enrolled 81 eligible study patients, of whom 80 were randomized (40 in the ferrous sulfate group and 40 in the iron polysaccharide complex group; Figure 1 ). The baseline demographic characteristics, laboratory values, and the percentage who received a packed red blood cell transfusion prior to enrollment were similar for both groups ( Table 1) . The mean age was 23 months and 55% were male. Sixty-one percent were Hispanic white, 9% were non-Hispanic white, and 11% were black. One child in the ferrous sulfate group erroneously received iron polysaccharide complex. This patient experienced treatment failure at week 8, was removed from study at that time, and was analyzed within the ferrous sulfate group. The other 79 patients received the intended treatment.
Primary Outcome
The mean hemoglobin concentration increased from 7.9 g/dL to 11.9 g/dL in the ferrous sulfate group compared with an increase from 7.7 g/dL to 11.1 g/dL in the iron polysaccharide complex group over 12 weeks (Figure 2) . The primary outcome (using a linear mixed model) demonstrated a significant difference in the change in hemoglobin concentration of 1.0 g/dL (95% CI, 0.4-1.6; P < .001) between the 2 groups, favoring ferrous sulfate. Ferrous sulfate
Iron polysaccharide complex
The error bars indicate 95% CIs. Using a linear mixed model, there was a significant difference in the change in hemoglobin concentration over time (1.0 g/dL [95% CI, 0.4-1.6 g/dL]; P < .001) between the 2 groups, favoring ferrous sulfate. 
Secondary Outcomes
The 59 patients who completed all study visits (28 in the ferrous sulfate group and 31 in the iron polysaccharide complex group) were analyzed for the predefined complete resolution of IDA (Table 2) , which occurred in a larger proportion of patients receiving ferrous sulfate (29%, n = 8) compared with those receiving iron polysaccharide complex (6%, n = 2) (P = .04). There were no significant between-group differences in iron measurements at baseline. The median serum ferritin level increased from 3.0 ng/mL to 15.6 ng/mL in the ferrous sulfate group compared with an increase from 2.0 ng/mL to 7.5 ng/mL in the iron polysaccharide complex group over 12 weeks (a greater difference of 10.2 ng/mL [95% CI, 6.2 to 14.1 ng/mL] with ferrous sulfate, P < .001; Table 3 ). The mean total iron-binding capacity decreased from 501 μg/dL to 389 μg/dL in the ferrous sulfate group compared with a decrease from 506 μg/dL to 417 μg/dL in the iron polysaccharide complex group over 12 weeks (a greater difference of −50 μg/dL [95% CI, −86 to −14 μg/dL] with ferrous sulfate, P < .001; Table 3 ).
Adverse Effects and Events
The adverse effect profiles demonstrated significantly more parent reports of diarrhea with iron polysaccharide complex ( Table 4 ). More parent reports of vomiting were made in the ferrous sulfate group; however, this difference was not statistically significant. A combined post hoc gastrointestinal adverse effect profile (abdominal pain, constipation, vomiting, and diarrhea) showed no significant between-group differences. One patient receiving ferrous sulfate experienced a transient episode of methemoglobinemia of unknown cause during week 4. The patient was successfully treated with methylene blue and continued in the study without recurrence.
Lost to Follow-up Rates
Sixteen percent of patients were lost to follow-up (7 [18%] in the ferrous sulfate group vs 6 [15%] in the iron polysaccharide complex group; P = .72). There were no significant differences in baseline characteristics (eTable 2 in Supplement 2) or adverse effects (eTable 3 in Supplement 2) between those patients who completed the study vs those who were lost to follow-up. Signs and Symptoms of IDA Both groups had improvements in patient-centered outcomes such as increased energy level, decreased pica, and resolution of pallor that were not significantly different ( Table 2) . None of the patients had an elevated blood lead level at the week 4 study visit.
Medication Adherence
Parents reported more successful administration of all individual iron doses (ie, the child not spitting out the medication) with iron polysaccharide complex (94% vs 82% in the ferrous sulfate group; P = .009). There were no other significant between-group measures for medication adherence.
Via patient diaries, 78% of families reported missing no doses of iron polysaccharide complex compared with 53% of families in the ferrous sulfate group (P = .12). Fifty percent of parents reported difficulty with administration of iron polysaccharide complex at any point in the study compared with 65% in the ferrous sulfate group (P = .17; Table 4 ). Returned medication volume indicated no significant difference in adherence with iron polysaccharide complex compared with ferrous sulfate. As a marker of difficulty with medication administration, there was no significant difference in the proportion of parents who reported mixing the iron preparation with juice or food ( Table 2) . 
Discussion
In this randomized clinical trial of infants and children aged 9 to 48 months with nutritional IDA treated at a single academic medical center, ferrous sulfate drops compared with iron polysaccharide complex drops resulted in a greater increase in hemoglobin concentration at 12 weeks. Studies of neurocognitive outcomes in children with IDA 17 have demonstrated the clinical importance of the between-group difference in hemoglobin concentration of 1 g/dL found in this trial. Among the secondary outcomes, the proportion of patients with a complete resolution of IDA (ie, no further iron therapy required) was higher in the ferrous sulfate group. Similar to the primary outcome, changes in iron indices favored the ferrous sulfate group. More parent reports of diarrhea were made in the iron polysaccharide complex group but no other significant differences in adverse effects were found. Patients were more likely to ingest the iron polysaccharide complex during administration compared with ferrous sulfate, but there were otherwise no significant between-group differences in the lost to follow-up rates, resolution of IDA symptoms, or medication adherence.
Iron salts have long been used for the treatment of IDA, with ferrous sulfate being the most common choice in persons of all ages.
16,20 Reports of poor taste and gastrointestinal adverse effects often result in the recommendation of other iron salts (eg, ferrous gluconate and fumarate) or iron polysaccharide complex preparations. 16, 21, 22 In the current trial, an iron polysaccharide complex agent developed specifically to have improved taste and tolerability was hypothesized to promote a more effective hematologic response. Although both preparations were effective and well-tolerated, ferrous sulfate resulted in a greater increase in hemoglobin concentration and improved diverse measures of iron homeostasis. Previous radioisotope studies have demonstrated more effective use of iron when administered in the form of medicinal iron in contrast to iron-fortified foods. 23 Small studies in adults suggest that bivalent salts such as ferrous sulfate are more effectively absorbed than trivalent ones. 24, 25 Limited data from prior studies suggest improved absorption with ferrous sulfate compared with iron polysaccharide complexes.
24,25
A small case series by Diamond et al 26 compared a palatable iron carbohydrate complex with ferrous sulfate, and the latter resulted in a more rapid hemoglobin concentration increase over 3 weeks. Oral iron absorption tests were conducted and those patients receiving ferrous sulfate demonstrated a markedly higher increase in serum iron, supporting the notion of more effective absorption. Therefore, this trial failed to demonstrate the original hypothesis that iron polysaccharide complex would be more effective than ferrous sulfate, likely due to more effective absorption of the latter.
Recommended therapeutic dosing of elemental iron in children ranges widely from 2 to 6 mg/kg/d administered from 1 to 3 times daily. 12 In this trial, a daily iron dose at the lower end of the recommended range (3 mg/kg of elemental iron) administered just once daily, at bedtime, and on an empty stom- Unlike nearly all prior therapeutic studies of oral iron agents, this trial was designed as a double-blind, randomized clinical trial. In concert with other literature, 13,14 these results should help stimulate the conduct of further clinical trials evaluating lower or less frequent dosing of oral iron. Anticipated outcomes might include improved patient adherence as well as enhanced iron absorption leading to a more favorable hematologic response.
Limitations
The trial has several limitations. First, it was conducted at a single tertiary care children's hospital. Second, there were a disproportionate number of lower income and minority patients whose anemia was often severe, with approximately 23% requiring a blood transfusion prior to enrollment. Third, the trial had a lost to follow-up rate of 25% at the final 12-week visit. Fourth, these results may not be generalizable to the general pediatric population due to the strict monitoring involved in a clinical trial compared with standard community practice. Yet by choosing to use a simplified dosing regimen, the goal was to create a practical treatment strategy that could improve outcomes even when applied in a clinical setting.
Conclusions
Among infants and children aged 9 to 48 months with nutritional iron-deficiency anemia, ferrous sulfate compared with iron polysaccharide complex resulted in a greater increase in hemoglobin concentration at 12 weeks. Once daily, low-dose ferrous sulfate should be considered for children with nutritional iron-deficiency anemia.
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Role of the Funder/Sponsor: The funders of the study had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript or the decision to submit for publication. 
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Texas, which is specifically formulated to improve palatability and absorption in young children.
100
To begin to address this problem of the sparse scientific literature supporting current therapies for IDA in infants 101 and children, we will conduct a superiority study of a once daily dose of 3 mg/kg elemental iron given as either 
169
ii. Subjects will be assigned to receive a single daily dose of 3 mg/kg elemental iron
170
(Please see Appendix II for study drug dosing.)
171
iii. Timing of study drug will be at bedtime. with baseline hemoglobin >8 gm/dL and those with baseline hemoglobin <8 gm/dL.
341
Within each stratum, subjects will then be randomly assigned to either experimental 342 group with a 1:1 allocation by a computer generated randomization schedule using 343 permuted blocks of 4.
344
ii. Concealment mechanism: Allocation concealment will be ensured by an investigational 345 pharmacist and will not take place until the patient has been recruited into the trial, after 346 all baseline measurements have been completed.
347
iii. Implementation: An investigational pharmacist will perform the sequence generation
348
and allocation concealment mechanism. Trial investigators will perform enrollment and 
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The primary hypothesis to be tested is that, compared to ferrous sulfate, NovaFerrum ® 384 produces a superior hematologic response in infants and young children with nutritional IDA.
385
The primary outcome will be the serial change in hemoglobin compared to baseline. The 
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In the above formula, we use to denote the measurement of outcome from patient at time
391
, the indicator of treatment (0 for ferrous sulfate and 1 for NovaFerrum ® ) for each patient,
392
and the residual effect which is assumed to be correlated within but independent between 393 subjects. Our primary interest is to test the null hypothesis , the rejection of which
394
suggests that subjects receiving NovaFerrum ® would have a different slope.
396
Of the secondary outcomes, the proportion of subjects with a complete response, the proportion 397 of subjects with various side effects, and the proportion of dropouts will be compared by the 
411
and is robust against deviation from the normality assumption.
413
For protocol deviation: The efficacy analysis will be conducted on the intention-to-treat (ITT)
414
population, which groups subjects based on their treatment assigned at randomization.
416

XVI. MONITORING
417
After 15 subjects are enrolled, local hospital compliance personnel will audit pharmacy and 
461
analyze all data without influence from this sponsor.
463
VI. ACCESS TO DATA
464
All trial investigators will be given direct access to the data sets.
466
VII. ANCILLARY AND POST TRIAL CARE
467
Participants who continue to have iron deficiency upon study completion will receive treatment at 468 discretion of their provider.
470
VIII. DISSEMINATION POLICY
471
Every attempt will be made to reduce the interval between completion of data collection and the Other factors at discretion of physician *The initial protocol required both serum ferritin <15 ng/mL AND total iron binding capacity >425 g/dL. A protocol modification to change the inclusion laboratory criteria was submitted to the Institutional Review Board on October 8, 2013. The first patient enrolled on the trial (under the revised criteria) on October 23, 2013 after confirming preliminary verbal approval from the Institutional Review Board; formal approval was received October 24, 2013.
+
Receipt of a packed red blood cell transfusion for severe symptomatic iron deficiency anemia upon presentation did not exclude a patient from potential enrollment. Post-transfusion blood counts were performed on all patients whose parents/guardians were interested in study participation in order to ensure that inclusion criteria were met prior to enrollment. 
(12)
(2) The presence of side effects was assessed (yes/no) every 2 weeks by investigators either in person or via telephone contact (weeks 2, 6, and 10 between visits). The assessment included abdominal pain, vomiting, and diarrhea, as well as distractors not expected to be related to study medication such as fever, difficulty breathing and itchy skin. Patient diaries were reviewed at face-to-face visits for reports of side effects including constipation, gas, upset stomach, dark stool, stained teeth and distractors of rash and stained nails. Parents had the option to report or comment on additional effects both in the diary and during the bi-weekly phone call.
Treatment Failure
At the 4 week visit, those patients with a lack of response in hemoglobin concentration (hemoglobin rise <0.5 gm/dL) were addressed with an increased emphasis on adherence. At the 8 week visit, if the hemoglobin concentration was <0.5 gm/dL above baseline assessment, the subject was considered a treatment failure, removed from the study and discontinued study drug. Further treatment was provided at the discretion of attending hematologist.
